- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2014
- Public Summary Document (PSD) March 2014 PBAC Meeting - PDF
Bevacizumab – March 2014
Bevacizumab, 100 mg/4 mL injection, 1 x 4mL vial and 400 mg/16 mL injection, 1x16 mL vial, Avastin®, Roche Products Pty Limited.
Last updated
8 November 2023